The promise of an experimental drug, offered by a small, distant clinic, is a powerful lure for any family facing a devastating illness. For the parents of Brody, a child whose medical condition falls outside the reach of established treatments, that lure is anchored in a novel piece of state legislation: Montana’s Right-to-Try law. This law, specifically designed to grant terminally ill patients access to investigational therapies that have not yet received federal approval, now finds itself at the center of a wrenching family dilemma and a high-stakes standoff with the U.S. Food and Drug Administration.
The law, known formally as the Expanded Treatment Right-to-Try (ETRB) program, creates a legal pathway within Montana for companies to sell unproven treatments directly to patients. The French biotech firm Ceres, which has developed a potential therapy for Brody’s condition, could theoretically use this Montana framework to offer its experimental drug to his family through a clinic in the state. Yet, the company’s CEO, Joudinaud, remains hesitant. While he acknowledges that Montana’s setup is “very interesting and very pragmatic” and, in his own words, “suitable for our drug,” he harbors a deep-seated fear of regulatory backlash. His reluctance stems from a single, unresolved question: will the FDA penalize a company that participates in such a state-run program when it later seeks formal marketing approval for its drug?
This question has become the central obstacle in the pursuit of treatment. For months, DeVault, Brody’s father, has been pleading with FDA staffers for a written guarantee. He wants a formal statement from the agency that it will not hold a company’s participation in Montana’s program against them during a future New Drug Application (NDA) review. The goal is straightforward: provide legal and regulatory cover for a company like Ceres to proceed without fear of career-ending or company-ending sanctions. So far, DeVault’s efforts have yielded no progress. The FDA, adhering to its traditional role as the gatekeeper of drug safety and efficacy, appears unwilling to pre-commit to such a hands-off stance.
Beyond Montana: The Search for a Haven in Honduras
Frustrated by the deadlock in the United States, DeVault is now looking far beyond the borders of Montana. He is actively considering an alternative pathway to treatment for his son, one that bypasses both state and federal oversight. His new target is Próspera, a private city and special economic zone located on the Honduran island of Roatán. Próspera operates under a unique governance structure that allows it to offer medical services, including experimental stem-cell and gene therapies, that are not approved by the FDA or other international regulatory bodies. Clinics in this zone market these unproven interventions directly to international patients, creating a modern-day medical frontier where risk and regulation are drastically redefined.
This shift from Montana to a foreign economic zone highlights the profound limitations and unintended consequences of state-level right-to-try laws. When a law fails to provide the certainty that companies and regulators need, families are forced to seek solutions in jurisdictions with even weaker safeguards. The allure of Próspera is simple: it offers a direct transaction between a desperate family and a willing provider, unencumbered by the bureaucratic and legal anxieties that paralyze companies like Ceres. For DeVault, the calculus is brutally personal. He sees the choice as between an uncertain but potentially life-altering therapy and a guaranteed future of watching his son’s condition worsen.
The Scientific Reckoning: What Phase I Trials Cannot Promise
The situation unfolding around Brody is not merely a story of parental perseverance; it is a case study in the fundamental tension between individual autonomy and public health safety. A chorus of scientists, bioethicists, and health law experts have raised serious alarms about the entire premise of Montana’s law and, more broadly, the rise of offshore clinics. Their primary concern centers on a basic scientific reality: a drug that has only completed Phase I clinical trials has proven nothing about its safety for a broad patient population and has demonstrated zero efficacy through a rigorous, controlled study.
Aaron Kesselheim, a professor of medicine at Harvard Medical School who specializes in health policy and drug regulation, articulated this discomfort with precision. When asked about the Montana law, he stated his concerns clearly. “Patients who want these kinds of treatments deserve them to be rigorously assessed so that [they] can better understand what they’re getting themselves into, and what they’re paying their hard-earned money for.” This perspective underscores the ethical obligation of the medical and scientific community to protect patients from interventions that lack a reliable evidence base. From this viewpoint, right-to-try laws, however well-intentioned, can create a dangerous loophole that exploits a patient’s vulnerability, offering false hope in exchange for significant financial cost and potential physical harm.
The Human Counter-Argument: A Right to Personal Decision-Making
DeVault, however, pushes back forcefully against these scientific and regulatory cautionary tales. He reframes the debate not as one of medical paternalism versus consumer freedom, but as a fundamental question of individual rights. “I’m a full-grown human being,” he argues, drawing a stark comparison to other legally permissible risks. “I’m capable of going to Vegas right now … blowing it all on the poker table, [or] I can go to the gun shop and buy a silenced [semi-automatic rifle] … how come I can’t make a decision to purchase a potential treatment that might change the entire trajectory of my son’s life?”
This argument is both emotionally powerful and logically provocative. It directly challenges the FDA’s role as a protector, suggesting that in the context of a terminal illness, the agency’s safety-first mandate becomes an obstacle to a patient’s last, best chance. DeVault is not asking for the drug to be approved for general use; he is asserting his right, as a competent adult, to take a calculated, informed risk on an unproven therapy. He is willing to accept the potential for failure and harm because the alternative—doing nothing—is, in his eyes, a guaranteed tragedy. His plea transforms the conversation from one about the science of the drug to one about the philosophy of personal autonomy and the limits of government regulation in the face of mortal peril.
The Practical Dilemma for Biotech Companies: Navigating a Gray Zone
The standoff highlights a critical, often overlooked obstacle to the success of right-to-try laws: the deep reluctance of biotech companies to participate. For a firm like Ceres, the risk is existential. Participating in Montana’s program could, in theory, provide revenue and valuable early data. However, the FDA maintains a long-arm reach over any drug that will eventually be submitted for its approval. Any misstep—or perceived violation of federal law—during an early-access program could be used as grounds for delaying or outright rejecting a future NDA. This creates a chilling effect. The very companies that possess the potential therapies are the ones most afraid to use the legal pathways created for them.
The ambiguity from the FDA is the root of the problem. Without a written statement of non‑enforcement, no company can confidently navigate the legal gray zone. Joudinaud’s position—finding the law “interesting” and “pragmatic” but fearing the FDA—is likely shared by many executives. Their reluctance is not a lack of compassion but a hard-nosed calculation of risk. They have spent years and millions of dollars developing a drug. A single, risky move under a state law could jeopardize the entire enterprise. Consequently, the law that was designed to expand access has, in practice, created a new barrier by failing to secure the cooperation of the industry it aims to mobilize.
Featured Snippet: What is Montana’s Right-to-Try Law?
Montana’s Right-to-Try law, known as the Expanded Treatment Right-to-Try (ETRB) program, is a state-level statute that permits terminally ill patients to access investigational drugs, biologics, and devices that have completed Phase I of a clinical trial but have not been approved by the U.S. Food and Drug Administration. The law allows companies to sell these unproven treatments directly to patients within the state, bypassing the standard FDA expanded access (compassionate use) process. Its goal is to accelerate access for patients with no other options, but its effectiveness is hindered by the reluctance of drug manufacturers who fear future regulatory reprisal from the FDA.
The High Cost of a Gamble: Financial and Medical Risks
While DeVault frames the decision as a personal choice comparable to gambling in Las Vegas, the medical and financial stakes in this scenario are incomparably higher. A single course of an experimental gene or stem-cell therapy can cost hundreds of thousands of dollars, a sum that must be paid out-of-pocket by families. Insurance companies will not cover unproven, unapproved treatments. This creates a brutal economic reality: access to hope is directly tied to a family’s financial reserves or ability to fundraise.
Beyond the financial toll, the medical risks are profound. Unproven therapies can cause severe, even fatal, adverse effects. Patients may experience organ failure, immune reactions, or the unintended consequences of a poorly understood biological intervention. Furthermore, by participating in an unregulated treatment, a patient may become ineligible for future, potentially more effective clinical trials. The decision to pursue a therapy in Próspera, for example, is not just a medical gamble; it is a strategic choice that can foreclose other options. The lack of rigorous oversight also means that the quality of the therapeutic product itself is unverified. There is no guarantee that the treatment a patient receives contains the advertised active ingredient, is sterile, or has been manufactured to any standard of consistency.
The Role of the FDA: Protector or Obstructionist?
The FDA’s unwillingness to provide a written waiver for companies like Ceres is not arbitrary. It stems from the agency’s core statutory mission: to ensure that drugs are safe and effective for their intended use. The FDA’s longstanding position is that early access to unproven therapies can undermine the clinical trial system, which is the gold standard for generating reliable evidence. If patients can simply buy a drug outside of a trial, it becomes exceptionally difficult to enroll the necessary number of subjects to complete a rigorous, statistically significant study. This, in turn, can delay or prevent the drug from ever being approved for the broader patient population that needs it.
The agency likely views DeVault’s request as a request to abandon its primary responsibility. By pre-committing to ignore a company’s participation in a state program, the FDA would be, in effect, endorsing a parallel regulatory system that it cannot control. This would set a dangerous precedent, potentially encouraging other states to enact similar laws and fragmenting the national drug approval process. For the FDA, the calculation is not about one family; it is about preserving the integrity of a global system that has, for decades, provided a reliable framework for bringing safe medicines to the public. The agency’s silence is, therefore, a strategic form of resistance.
The Rise of the Medical Diaspora: Offshore Zones as the Next Frontier
DeVault’s consideration of Próspera is emblematic of a growing trend: the rise of medical tourism to special economic zones and weakly regulated countries. These destinations position themselves as hubs for medical innovation, offering treatments that are illegal or prohibitively expensive in the patient’s home country. For families on the margin of hope, the allure is obvious. It represents a clean, contractual transaction, free from the moral and regulatory debates that plague domestic options.
This “medical diaspora” has significant implications for global health governance. It creates a two-tiered system of biotechnology access: one for the wealthy and desperate who can travel to exotic locations and pay cash for experimental therapies, and another for everyone else, who must wait for the slow, painstaking process of conventional clinical trials and FDA approval. The existence of these zones also puts pressure on regulators in the United States and Europe. If companies and patients can find a loophole abroad, the authority and moral standing of domestic regulatory bodies are implicitly challenged. The FDA may find that its greatest competitor is not another federal agency but a private city on a Caribbean island.
What Are the Dangers of Offshore Stem-Cell and Gene Therapy Clinics?
Many scientists have cautioned against the use of these “offshore” clinics. The primary dangers are multifaceted. First, there is the risk of receiving an adulterated or non-sterile product, which can cause life-threatening infections. Second, the long-term effects of unproven gene therapies are entirely unknown; they could lead to unintended genetic changes or cancers. Third, patients are often provided with incomplete or misleading information about the potential benefits and risks, creating a scenario where informed consent is compromised. Finally, there is no legal recourse in these jurisdictions if a treatment causes harm; the patient or their family has no ability to seek damages through a trusted legal system. The risk is not just that the treatment might fail, but that it might actively cause catastrophic harm.
The Unanswered Question: How Much Is a Life Worth?
At the heart of this story lies an uncomfortable, unanswerable question: how much should a society allow a family to risk in the pursuit of a potential cure? DeVault’s argument for personal autonomy is compelling. He is not asking for a handout or a guarantee. He wants the right to spend his own money on an experimental drug, fully aware that it might not work and might even harm his son. This is the purest expression of the libertarian spirit that underpins many right-to-try laws.
Yet, the counter-argument from experts like Kesselheim is equally compelling. It insists that a society has a collective responsibility to protect its most vulnerable members from exploitation, even—or especially—when they are most desperate. The tension between these two positions is the central conflict of modern bioethics. It plays out not only in Montana and Honduras but in hospitals, legislatures, and families across the world. The resolution is never clean, and the stakes are always a human life.
A Future of Fragmented Access: The Unresolved Standoff
As DeVault and his son Brody stand at this crossroads, the path forward remains uncertain. The biotech company Ceres is hesitant, the FDA is silent, and the Honduran special economic zone beckons. The Montana Right-to-Try law, a piece of legislation intended to empower families, has instead highlighted the deep fissures in the system. It has shown that a law is only as effective as the willingness of the regulated industry to use it and the tolerance of the dominant regulator to allow it.
The ultimate resolution for this family—and for the thousands of others watching their story—will set a powerful precedent. If DeVault successfully brokers a deal in Próspera, it could accelerate the trend of patients fleeing the American regulatory system. If the FDA eventually grants a waiver, it could unlock the potential of state right-to-try laws. If Ceres relents and uses the Montana pathway, it could prove that a dual system is viable. For now, the situation remains a standoff of values: science against autonomy, safety against hope, and the long game of public health against the immediate, desperate needs of a single family. The world is watching to see which principle will prevail.
